D. Boral Capital Reaffirms “Buy” Rating for CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reaffirmed by analysts at D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $14.00 target price on the stock. D. Boral Capital’s price target would indicate a potential upside of 449.02% from the company’s previous close.

Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Price Performance

NASDAQ:CLGN opened at $2.55 on Thursday. The company has a market capitalization of $29.21 million, a P/E ratio of -1.66 and a beta of 1.07. The business has a fifty day simple moving average of $3.44 and a two-hundred day simple moving average of $3.93. CollPlant Biotechnologies has a 1 year low of $2.54 and a 1 year high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, March 26th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.08. The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.36 million. CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. As a group, analysts anticipate that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Trading of CollPlant Biotechnologies

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its holdings in CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after buying an additional 4,405 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of CollPlant Biotechnologies in the fourth quarter valued at approximately $38,000. Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies during the third quarter valued at approximately $112,000. Finally, AMH Equity Ltd increased its holdings in CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after acquiring an additional 17,295 shares during the period. Hedge funds and other institutional investors own 21.69% of the company’s stock.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.